Third-Quarter Sales Decline on Recalled Medicines
This article is for subscribers only.
Johnson & Johnson, the world’s largest health-products company, reported third-quarter revenue that missed analysts’ estimates as recalls of children’s medicines hurt sales of consumer products.
Total sales fell 0.7 percent to $15 billion, missing the $15.2 billion estimate of 16 analysts surveyed by Bloomberg. J&J declined as much as 2.1 percent in New York Stock Exchange composite trading.